Latest news

ESMO Important dates

Uploaded 26th July

  • ESMO Virtual Preceptorship on Head and Neck Cancer, 24-25 September 2021 - Online Application deadline: 4 August 2021

  • ESMO Virtual Preceptorship on Gastric Cancer, 17-18 November 2021 - Online Application deadline: 22 September 2021

NZSO ESMO regular image 1

The Breast Cancer Foundation NZ is preparing the application form for their next Fellowship round

In the last few years, they have received very few applications for our science fellowship, and none at all for our clinical fellowship. Two other major breast cancer fellowship funders (one in NZ, one in Australia) tell us they’ve had a similar experience.

This fellowship of up to $120,000 is not being applied for, and they would like some input on what needs to be changed.

NZSO ESMO regular image 2

Empowering Precision Oncology through Genomics

Uploaded 26th July

Date: 29th August 2021, Sunday (1 day prior to QRW)

Location: Von Room, QT Queenstown (Physical Meeting)

Time: 09:00 am - 05:30 pm (NZT)

Keynote Speakers:

Prof. Cris Print, University of Auckland

Prof. Stephen Fox, Peter MacCallum Cancer Centre

Prof. Clare Scott, Walter and Eliza Institute of Medical Research

Assoc. Prof. Aniruddha Chatterjee, University of Otago

Prof. Kenneth O’Byrne, Princess Alexandra Hospital

ZNSO OT NZ Precision Oncology Workshop Social

2021 New Zealand Melanoma Summit | 10 – 12 September 2021 Auckland

Uploaded 26th July

Focused on the changing landscape of melanoma care in New Zealand and proactive, collaborative action to improve our world leading rates, this two-day multi-disciplinary meeting will officially launch the Quality Statements to Guide Melanoma Diagnosis and Care in New Zealand. Be part of this important conversation, improve your knowledge of best practice melanoma care and connect with other passionate health professionals. With a superb line up of internationally recognised experts, interactive workshops on prevention, diagnosis, clinical management and research, and an optional Certificate of Fundamental Dermatoscopy on the third day, this is an event not to be missed.

NZSO Melnet Banner 2 Square

Cancer Research Trust Grant Round

Uploaded 26th July

Cancer Research Trust NZ is pleased to announce the closing dates for the 2021 main grant round

Research projects may be in the field of cancer-related public health, or the biomedical, clinical, epidemiological or psychosocial aspects of cancer. Initiatives in the field of Palliative care will also be considered. Our grant round is highly competitive with fewer projects able to be funded than we would like, but we give equal consideration to projects throughout the cancer control continuum.

Closing date Friday September 1st 2021

Professional Development Awards Round 2 (Max $3,000 – for travel after Jan 1st 2022). There will be another PDA round in April 2022 for Travel after June 1st 2022.

NZSO cancer research trust

Precision Oncology Issue

Uploaded 26th July

Roche has commissioned Dr Angela George (Clinical Director of Genomics at the Royal Marsden Hospital in London) to be the consulting editor on this newsletter, Perspectives of Precision Oncology. This is issue 1 of 5 to be released in 2021, and will include follow on from ASCO meeting, as well as NZSO’s meeting.

Lymphoma and Leukaemia Research Review

Uploaded 20th July 2021

The Release of the “Position Statement: Role of the oncology pharmacy team in cancer care

Uploaded 20th July 2021

Vancouver, BC (July 8, 2021) – The International Society of Oncology Pharmacy Practitioners (ISOPP) is pleased to announce the publication of its “Position Statement: Role of the oncology pharmacy team in cancer care” in the Journal of Oncology Pharmacy Practice (JOPP).

The Position Statement describes the roles of oncology pharmacists and technicians in cancer patient care and provides information that promotes advocacy, especially for countries where the profession has not yet recognized oncology pharmacy as a specialty.

ISOPP developed the Position Statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the oncology pharmacy team (OPT).

The Position Statement advocates that: 1) the OPT be fully incorporated into the multidisciplinary healthcare team to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.

View the Position Statement at:

ISOPP thanks the 23 ISOPP members, led by co-chairs Barry Goldspiel and Lisa Holle, representing 10 countries for writing the Position Statement.

ASCO Leadership Development Program Asia Pacific

The ASCO Leadership Development Program for the Asia-Pacific region (LDP-AP) teaches culturally-relevant skills in leadership, advocacy, communication, presentation skills, media skills, and conflict management. Participants will be selected based on their commitment to improving cancer care and potential for leadership. At the conclusion of the program, participants will be better able to lead successful advocacy efforts, to build relationships with leaders within their countries, and to lead within their own societies, institutions, and ASCO.

Program Objective – Bring together a diverse pan-Asian interdisciplinary group of emerging leaders in oncology who are empowered to identify and fill leadership roles in oncology, to engage in advocacy efforts, and to promote interdisciplinary collaboration across the region and within ASCO.

Program Highlights Participants will learn skills through both virtual and in-person sessions. They will participate actively in small group discussions, small group projects, and a 2-3 day in person workshop.

To apply for the ASCO Leadership Development Program Asia Pacific, applicants must:

  • Be an ASCO Member (or submit a membership application in conjunction with the application)
  • Commit to participating in monthly virtual learning sessions, small group projects, and one in-person workshop to be held August 25-27 in Japan.
  • Meet English language fluency requirements

NOTE: The Leadership Development Program Asia Pacific includes mandatory participation in the in-person workshop to be held at the Breakthrough Meeting in Yokohama, Japan, August 25-27, 2022. Travel expenses for participants will be provided.

Key Dates

Online Application Open: May 18, 2021
Application Due: June 30, 2021
Notifications: September 10, 2021
Program Period: November 2021 - November 2022
In-person Seminar: August 25-27, 2022 (Breakthrough in Yokohama Japan)

If you have questions about the ASCO Leadership Development Program Asia Pacific, please email

2022 RACP Foundation Research Awards

Applications are now open for the RACP Foundation Research Awards, which provide research funding for 2022. Up to 50 awards up to a total value of $2.5 million and are available to RACP Fellows and trainees from Australia and Aotearoa New Zealand.

Funding is available in the following categories:

Applications for Education Development Grantsfor funding in 2021 and Research Development Scholarships and Travel Grants for funding in 2022 will open Monday, 1 June 2021.

Awards which may be of interest for your members include:

  • Arnott Research Entry Scholarship in Cancer Research
  • The Servier Staff "Barry Young" Research Establishment Fellowship
  • RACP GSK Research Establishment Fellowship

Full details for these opportunities including eligibility and application closing dates are available on the RACP Foundation Research Awards webpage.

Please forward this email to colleagues who may be interested in applying for these or the other awards available.

Should you have any questions, please email us.

Notice of discontinuation of CeeNU Australia and New Zealand

Bristol Myers Squibb would like to inform you that the sale and distribution of CeeNU (lomustine) will be discontinued in Australia and New Zealand in December 2022. This discontinuation includes all dose strengths (10mg and 40mg). The decision to discontinue CeeNU is due to declining demand and the availability of newer, preferred therapies (recommended by current treatment guidelines) for the treatment of brain tumours, such as glioblastomas. As such, the decision to discontinue CeeNU is voluntary and not related to any quality, safety or efficacy issues regarding the product.

NZSO Bristol meyers squibb

Welcome to the sixth issue of Skin Cancer Research Review.

This issue includes research reporting that patients who relapse after adjuvant targeted therapy for BRAFmutated stage III melanoma respond well to subsequent anti-PD-1-based therapy with outcomes similar to those seen with first-line anti-PD-1 therapy for stage IV melanoma. We have also included a long-term safety report from three of the KEYNOTE trials of pembrolizumab monotherapy for melanoma. Research conducted in participants from a dermoscopy masterclass found that the accuracy of diagnosing lentigo maligna improved after they were trained in the inverse approach, added to the classic pattern analysis. This issue concludes with an Australian study investigating discrepancies between biopsy results and final excised specimens in keratinocyte carcinomas.

We hope you enjoy the research selected, and we look forward to your comments and feedback.

Kind regards,
Dr Annie Wong

Are you a doctor, nurse or allied healthcare professional working in Aotearoa?

We invite Maori and non-Maori healthcare professionals who have provided care for patients with cancer to take part in a brief online survey. iPad Mini up for grabs.

Click here to start the survey.

The call for nominations for medals and awards for the 2021 round is now open.

Please note that the Academy Executive Committee is focused on increasing the diversity of nominations from under-represented groups, particularly with respect to gender, ethnicity and employment context, from Crown Research Institutes and Independent Research organisations.

Podcast episode featuring Diana Safartis

Please see below the podcast episode featuring a really in-depth interview with Diana Safarti, discussing Global Disparity of Cancer Care and specifically in the Pacific. Here’s the link for you to listen:

To subscribe to Oncology News Australia, which includes a mix of conference coverage, reviews, news, opinion pieces, podcasts –

NZSO Openness Agreement

Openness Agreement on the use of animals in research and teaching in New Zealand

Foreword from Professor Juliet Gerrard, The Prime Minister’s Chief Science Advisor:

Why the Openness Agreement was developed?

The Australia New Zealand Council for the Care of Animals in Research and Teaching (ANZCCART) is an independent body that was established to provide a focus for consideration of the scientific, ethical and social issues associated with the use of animals in research and teaching. After years of promoting openness in animal research, ANZCCART has taken the lead in developing this Agreement

Important research featured on Newshub

from our very own Executive Member, Associate Professor Logan Walker

Click here to see the importance of mandatory genetic screenings for women diagnosed with breast cancer.

NZSO Loganwalker news

2021 New Zealand Annual Scientific Meeting

On behalf of the Royal Australian and New Zealand College of Radiologists (RANZCR) and the 2021 NZ ASM Organising Committee, we are happy to confirm

Friday 6 - Sunday 8 August 2021 | The InterContinental Hotel | Wellington, New Zealand

Given the continuing restrictions on international travel, our overseas speakers have confirmed that they will join us remotely – with pre-recorded presentations and then real-time participation with delegates for live Q & A:


Professor Laurie A. Loevner, Chief, Division of Neuroradiology, Professor of Radiology, Neurosurgery, Otorhinolaryngology: Head & Neck Surgery and Ophthalmology, University of Pennsylvania Health System, USA.
Specialty Interests: Head and Neck, Neuroradiology

Associate Professor Bruno Giuffrè, University of Sydney at Northern Clinical School, Radiology Department, Royal North Shore Hospital, Sydney, Australia.
Specialty Interests: Musculoskeletal, RheumatologyAssociate

Radiation Oncology

Associate Professor Corrine Doll, Tom Baker Cancer Center, President of Canadian Association of Radiation Oncology, Calgary, Canada.
Specialty Interests: Gynecologic, Gastrointestinal Cancer Rheumatology

Registration and Abstract Submissions open on 8 April. For more information:

NZSO RANZCR Illustrated Logo 01